Genzyme Corp., Biogen Idec, McDonald’s: U.S. Equity Movers
Tags:
Biogen
Corp
Equity
Genzyme
Idec
McDonald
Movers
General
Monday, 26 July 2010
Genzyme Corp., Biogen Idec, McDonald’s: U.S. Equity Movers
Shares of the following companies are having unusual moves in U.S. trading. Stock symbols are in parentheses, and prices are as of 2 p.m. in New York.
More...
Biogen Idec Looks Bullish on Earnings Guidance
Tags:
Biogen
Bullish
Earnings
Guidance
Idec
Looks
General
Wednesday, 21 July 2010
Biogen Idec Looks Bullish on Earnings Guidance
Filed under: Earnings Reports, Stocks to Buy Biogen Idec (BIIB) improved its bullish prospects today as it announced earnings of $1.31 per share -- well above the Wall Street consensus estimate of $1.12 -- and raised its 2010 earnings outlook.
Total revenue for last quarter -- thanks in large part to better-than-expected sales of Biogen's multiple sclerosis drug Avonex -- came in at $1.2 billion, up 11% year over year.
Perhaps most exciting, however, was Biogen's announcement that it is raising its guidance for 2010 earnings to $4.70 per share, up from the current consensus of $4.57. Continue reading Biogen Idec Looks Bullish on Earnings Guidance Biogen Idec Looks Bullish on Earnings Guidance originally appeared on BloggingStocks on Tue, 20 Jul 2010 11:30:00 EST. Please see our terms for use of feeds. Permalink | Email this | Comments
Multiple sclerosis - Biogen Idec - BloggingStocks - Wall Street - Health
More...
Post Earnings, Biogen Idec (BIIB) Sees Unusual Options Activity
Tags:
BIIB
Biogen
Earnings
Idec
Options
Post
Sees
Commodities
Saturday, 30 January 2010
Post Earnings, Biogen Idec (BIIB) Sees Unusual Options Activity
Filed under: Earnings Reports, OptionsAs my colleague Karla Yeh pointed out over at ONN.tv earlier today, Biogen Idec (BIIB) saw some unusual options trading in the wake of its positive earnings surprise before the bell. BIIB gapped higher at the open, jumping almost 2% out of the gate. Less than a half hour into the trading day, large blocks of roughly 4,000 contracts each traded at four March strikes: the 45-strike put, the 50-strike put, the 55-strike call, and the 60-strike call. It appears as though this investor sold the March 50/55 strangle (the 50 put and the 55 call) and simultaneously purchased the March 45/60 strangle (the 45 put and the 60 call). A short strangle is typically employed when the investor expects the underlying instrument to stay range-bound; a long strangle is used by traders who expect a sharp move in either direction. In this case, with one of each crossing the tape as part of one strategy, it can be referred to as an iron condor.Continue reading Post Earnings, Biogen Idec (BIIB) Sees Unusual Options ActivityPost Earnings, Biogen Idec (BIIB) Sees Unusual Options Activity originally appeared on BloggingStocks on Tue, 09 Feb 2010 15:00:00 EST. Please see our terms for use of feeds.Read | Permalink | Email this | Comments
More...
CEO Mullen sells $7M in Biogen Idec stock
Tags:
Biogen
CEO
Idec
Taxes
Wednesday, 23 December 2009
CEO Mullen sells $7M in Biogen Idec stock
Biogen Idec President and CEO James Mullen has sold 147,037 shares of his company's stock, a stake worth almost $7.4 million, according to a U.S. Securities and Exchange filing
More...
Biogen Idec names new chairman, announces positive drug test results
Tags:
Biogen
Idec
Investing
Saturday, 12 December 2009
Biogen Idec names new chairman, announces positive drug test results
Filed under: Good news, Products and services, Lilly (Eli) (LLY)Biogen Idec (BIIB) has made a bit of news the past two days, starting with Thursday's news that William Young is the company's new chairman of the board. BIIB's Bruce Ross will complete his term as director and will step down from the board at BIIB's 2010 shareholder meeting. William Young will take over effective January 1, 2010. Young is a veteran of the biotech industry, as he served with Monogram Biosciences, Genentech (where he was CEO), and Eli Lilly. Ross noted, "I am pleased the Board has selected Bill Young as Biogen Idec's new Chairman. He is an experienced biotechnology and pharmaceutical industry executive with an extensive understanding of Biogen Ides, given his 12 years of service as a director of the company."Continue reading Biogen Idec names new chairman, announces positive drug test resultsBiogen Idec names new chairman, announces positive drug test results originally appeared on BloggingStocks on Fri, 11 Dec 2009 11:40:00 EST. Please see our terms for use of feeds.Permalink | Email this | Comments
More...
Zacks Industry Outlook Highlights: Alcon, Novartis, Gilead Sciences, Biogen Idec and Acorda Therapeutics (Business Wire)
Tags:
Biogen
Business
Gilead
Idec
Industry
Novartis
Outlook
Wire
Zacks
Commodities
Monday, 09 November 2009
Zacks Industry Outlook Highlights: Alcon, Novartis, Gilead Sciences, Biogen Idec and Acorda Therapeutics (Business Wire)
CHICAGO----Zacks.com releases the latest Industry Outlook. Today, Zacks Equity Research discusses the Big Pharma & Biotech Industry, including Alcon , Novartis , Gilead Sciences , Biogen Idec and Acorda Therapeutics
More...
Biogen Idec Extends Offer to Acquire Facet Biotech Corporation for $14.50 Per Share in Cash (Business Wire)
Tags:
Biogen
Biotech
Business
CASH
Cash
Corporation
Extends
Idec
Offer
Per
Share
Wire
Stocks and Options
Thursday, 15 October 2009
Biogen Idec Extends Offer to Acquire Facet Biotech Corporation for $14.50 Per Share in Cash (Business Wire)
CAMBRIDGE, Mass.----Biogen Idec Inc. announced today that it has extended the tender offer by its wholly owned subsidiary, FBC Acquisition Corp., to purchase all of the outstanding shares of Facet Biotech Corporation to 12:00 midnight New York City time on December 16, 2009, unless otherwise extended
More...
Zacks Analyst Blog Highlights: Sanofi-Aventis, Biogen-Idec, Marathon Oil Corporation, Shell and StatoilHydro (Business Wire)
Tags:
Analyst
Biogen
Business
Corporation
Idec
Marathon
Oil
Sanofi
Shell
StatoilHydro
Wire
Zacks
Commodities
Friday, 26 June 2009
Zacks Analyst Blog Highlights: Sanofi-Aventis, Biogen-Idec, Marathon Oil Corporation, Shell and StatoilHydro (Business Wire)
CHICAGO----Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets
More...
Biogen Idec Sends Letter to Stockholders (Business Wire)
Tags:
Biogen
Business
Idec
Letter
Sends
Stockholders
Wire
Investing
Tuesday, 26 May 2009
Biogen Idec Sends Letter to Stockholders (Business Wire)
CAMBRIDGE, Mass.----Biogen Idec today announced that it has sent to its stockholders a letter urging them to vote Biogen Idec's WHITE proxy card FOR all of the Company's Board of Directors' highly regarded and experienced nominees
More...
|
Latest News
Recently updated
|